References

Juhász MLW, Curley RA, Rasmussen A, Malakouti M, Silverberg N, Jacob E. Systematic review of the topical steroid addiction and topical steroid withdrawal phenomenon in children diagnosed with atopic dermatitis and treated with topical corticosteroids. Journal of the Dermatology Nurses’ Association: September/October 2017 – Volume 9 – Issue 5 – p 233–240 doi: 10.1097/JDN.0000000000000331

Sheary, Belinda. Topical corticosteroid addiction and withdrawal–An overview for GPs. Australia Family Physician. 2016;45(6):386-388.

Fukaya, M, Sato K, Yamada T, et al. A prospective study of atopic dermatitis managed without topical corticosteroids for a 6-month period. Clin Cosmet Investig Dermatol. 2016; 9:151-158.  doi: 10.2147/CCID.S109946

Novak E and Allen PJ. Prescribing medications in pediatrics: Concerns regarding FDA approval and pharmacokinetics. Pediatric Nursing. 2007; 33(1):64-70.

Rapaport MJ and Rapaport VH. Serum nitric oxide levels in “red” patients: Separating corticosteroid addicted patients from those with chronic eczema. Arch Dermatol. 2001;140(8):1013-1014.

Fukaya M. Histological and Immunohistological Findings Using Anti-Cortisol Antibody in Atopic Dermatitis with Topical Steroid Addiction. Dermatology and Therapy. pp. 1-8. 2/2/2016. Accessed 2/4/16 at link.springer.com/article/10.1007/s13555-016-0096-7/fulltext.html    doi:10.1007/s13555-016-0096-7

Eichenfield LF, Boguniewicz M, Simpson, EL, Russell JJ, Block JK, Feldman SR, et al. Translating atopic dermatitis Management Guidelines into practice for primary care providers. Pediatrics. 2015;136(3):554-565.  doi: 10.1542/peds.2014-3678

Eichenfield LF, Tom WL, Chamlin SL, Feldman SR, Hanifin JM, Simpson, EL, et al. Guidelines of care for the management of atopic dermatitis. Section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol 2014;70:338-51.

Eichenfield L, Tom W, Berger T, et al. Guidelines of care for the management of atopic dermatitis Section 2 Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014; 71(1):121-124.

DOI:http://dx.doi.org/10.1016/j.jaad.2014.03.023National Eczema Association. “Risk of topical corticosteroids” under Eczema treatment/topical steroids. Online. Copyright 2015. Accessed on 1/31/15. http://nationaleczema.org/eczema/treatment/topical-corticosteroids/risks-of-topical-corticosteriods/

National Eczema Association. “Eczema prevention checklist” under Eczema treatment. Online. Copyright 2015. Accessed on 1/29/15. http://nationaleczema.org/eczema/treatment/

Fukaya M, Sato K, Sato M, et al. Topical steroid addiction in atopic dermatitis. Drug, Healthcare Patient Safety. 2014:6 131. DOI: http://dx.doi.org/10.2147/DHPS.S69201

Hajar T, Leshem YA, Hanifin JM, Nedorost, ST, Lio PA, et al. A systematic review of topical corticosteroid withdrawal (“steroid addiction”) in patients with atopic dermatitis and other dermatoses. J Am Acad Dermatol. 2015 Mar;72(3):541-549.e2. Epub 2015 Jan 13. DOI: http://dx.doi.org/10.1016/j.jaad.2014.11.024

Rapaport MJ, Rapaport V. The Red skin syndromes: corticosteroid addiction and withdrawal. Expert Rev. Dermatolo. 2006;1(4):547-561.

Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol 2006;54:1-15.

Kligman AM, Frosch PJ. Steroid addiction. International Journal of Dermatology Jan. 1979; 18(1):23-31.

Rapaport MJ, Rapaport V. Eyelid dermatitis to red face syndrome to cure: clinical experience in 100 cases. J Am Acad Dermatol. 1999 Sept;41(3 Pt 1):435-42.

Rapaport MJ, Lebwohl M. Corticosteroid addiction and withdrawal in the atopic: the red burning skin syndrome. Clin Dermatol. 2003 May-Jun; 21(3):201-14.

Rapaport MJ, Rapaport V. The Red skin syndromes: corticosteroid addiction and withdrawal. Expert Rev. Dermatolo. 2006;1(4):547-561.

Michael J Cork, Simon G Danby, Yiannis Vasilopoulos, Jonathan Hadgraft, Majella E Lane, Manar Moustafa, Richard H Guy, Alice L MacGowan, Rachid Tazi-Ahnini and Simon J Ward. Epidermal Barrier Dysfunction in Atopic Dermatitis. Journal of Investigative Dermatology (2009) 129, 1892–1908.  doi:10.1038/jid.2009.133; published online 4 June 2009.

Weaver J. Post-marketing Safety Review–PID D0141 Drugs: Topical Corticosteroids (FDA Memorandum). July 9, 2001. http://www.fda.gov/ohrms/dockets/ac/03/briefing/3999B1_21_Weaver-Memo%2007-09-01.htm

Ghosh A, Sengupta S, Condo A, Jana A. Topical corticosteroid addiction and phobia. Indian J Dermal. 2014 Sept-Oct; 59(5):465-468. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4171914/?report=reader

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s